Galectin Therapeutics Inc. — FY2013 Form 10-K Summary
Business context and reporting period
Galectin Therapeutics is a development-stage biotechnology company focused on galectin-targeting therapies for fibrosis and cancer. The filing covers the fiscal year ended December 31, 2013; it is an annual Form 10-K rather than a standalone fourth-quarter filing.
- Lead candidate: GR-MD-02 for NASH with advanced liver fibrosis and for combination cancer immunotherapy.
- Additional candidate: GM-CT-01, primarily investigated in cancer therapy.
- The company had no approved products, no commercial sales, and no revenue through December 31, 2013.
Financial condition and key metrics
| Metric | FY2013 | FY2012 | Change |
|---|---|---|---|
| Revenue | None | None | No revenue to date |
| Research and development expense | $5.688 million | $4.527 million | Up 26% |
| General and administrative expense | $6.416 million | $5.372 million | Up 19% |
| Total operating expenses | $12.104 million | $9.899 million | Up $2.205 million |
| Net loss | $12.088 million | $9.675 million | Higher loss |
| Net loss applicable to common stockholders | $21.947 million | $10.881 million | Higher primarily due to warrant modification |
| Basic and diluted loss per share | $1.30 | $0.72 | Higher loss per share |
| Net cash used in operating activities | $7.484 million | $7.500 million | Down $16,000 |
| Net cash from financing activities | $8.609 million | $10.403 million | Lower financing proceeds |
| Cash and cash equivalents at year-end | $10.489 million | $9.364 million | Up $1.125 million |
Operating expenses increased as the company advanced GR-MD-02 into clinical testing. FY2013 clinical and preclinical spending included approximately $1.892 million related to the Phase 1 trial. General and administrative expense included increased stock-based compensation, legal costs, insurance, and investor-relations expense.
The balance sheet showed total assets of $10.713 million, total liabilities of $2.486 million, redeemable convertible preferred stock of approximately $6.746 million, and stockholders’ equity of $1.481 million. The company reported no warrant liabilities at year-end and no material debt balance was identified in the filing.
Cumulative net loss applicable to common stockholders since inception was $102.221 million, and accumulated development-stage deficit was $101.965 million. The company had raised approximately $77.4 million through financing transactions through December 31, 2013.
Material changes versus the prior comparable period
- R&D expense rose 26% as GR-MD-02 entered a U.S. Phase 1 trial for NASH with advanced fibrosis.
- G&A expense rose 19%, including a $930,000 non-cash charge from extending the exercise period of certain former director stock options.
- A one-time $8.763 million non-cash warrant-modification charge was recorded in 2013 after extending the terms of certain 10X Fund warrants. This materially increased the loss applicable to common stockholders.
- The company issued 500,000 common shares in a private placement for $3.0 million and generated approximately $833,000 in net proceeds under its ATM program during 2013.
- Outstanding warrants declined to 6.035 million at year-end from 7.424 million, while outstanding options declined to 3.349 million from 3.540 million.
- GR-MD-02 received FDA Fast Track designation for NASH with hepatic fibrosis in August 2013.
Guidance, outlook, commentary, risks and unusual items
- The first cohort of the GR-MD-02 Phase 1 trial was completed in January 2014 without reported serious adverse events. Initial safety, tolerability, and biomarker results were expected in early April 2014.
- A second Phase 1 cohort was expected to begin around April 2014. Subject to results, management expected to begin a Phase 2 trial in late 2014 or early 2015, with initial Phase 2 results anticipated in the first half of 2016.
- An investigator-sponsored Phase 1B study of GR-MD-02 with Yervoy for metastatic melanoma was initiated after FDA approval of the related IND in February 2014.
- In January 2014, the Phase 1/2 GM-CT-01 melanoma trial was placed on hold because investigators could not enroll sufficient eligible patients. The filing states the halt was not attributed to safety concerns or perceived drug effects; three patients had completed the protocol without serious adverse events.
- Management stated that cash, including approximately $28.178 million of net ATM proceeds and $1.5 million from warrant exercises received in January and February 2014, was expected to fund currently planned operations through 2015. Additional capital is required thereafter.
- The company has incurred losses every year since inception and warned that inability to raise additional capital after 2015 could require significant curtailment of operations or bankruptcy protection.
- A $1.0 million severance obligation to former CEO David Platt remained accrued. Arbitration seeking to rescind or reform the separation agreement was scheduled for May 2014; the amount could be reversed or could become payable, potentially with additional damages, interest, and attorneys’ fees.
- Key risks include unsuccessful or delayed clinical trials, regulatory failure, patient-enrollment challenges, reliance on contract manufacturers and clinical research organizations, limited operating history, dependence on future equity financing, dilution, intellectual-property challenges, competition, and stock-price volatility.
- The company relies on third parties for manufacturing and does not maintain internal commercial manufacturing, sales, or marketing infrastructure.
Most important facts for investors to verify
- Confirm the audited financial statements and the reported $21.947 million net loss applicable to common stockholders, including the $8.763 million non-cash warrant-modification charge.
- Review post-year-end financing proceeds and resulting share dilution, including the January-February 2014 ATM issuance and warrant exercises.
- Verify actual GR-MD-02 Phase 1 safety, tolerability, biomarker, and subsequent Phase 2 results against management’s stated timetable.
- Monitor the status and outcome of the GM-CT-01 melanoma trial hold and the investigator-sponsored GR-MD-02/Yervoy study.
- Assess liquidity beyond 2015 and the company’s ability to obtain additional financing on acceptable terms.
- Review the Platt arbitration, related litigation, the accrued $1.0 million obligation, and any potential additional liability.
- Evaluate dilution from approximately 6.035 million outstanding warrants, 3.349 million options, and preferred-stock conversion rights representing approximately 2.569 million common shares.